CA3094431C — Pharmaceutical composition including sodium alkyl sulfate
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2023-06-27 · 3y expired
What this patent protects
The object of the present invention is to improve the dissolution and the absorption of (S)-1-(3-(4-amino-3-((3,5-ditnethoxyphenyeethyny1)-1H-pyrazolo [3 ,4-d]pyrimidin-1-y1)-1-pyrrolidiny1)-2-propen- 1 -one effective as an antitumor agent from a pharmaceutical formulation compri…
USPTO Abstract
The object of the present invention is to improve the dissolution and the absorption of (S)-1-(3-(4-amino-3-((3,5-ditnethoxyphenyeethyny1)-1H-pyrazolo [3 ,4-d]pyrimidin-1-y1)-1-pyrrolidiny1)-2-propen- 1 -one effective as an antitumor agent from a pharmaceutical formulation comprising the same. Provided is a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenypethyny1)-1H-pyrazolo[3,4-d]pyrimidin-1-y1)-1-pyrrolidiny1)-2-propen-1-one ("Compound A") in combination with sodium alkyl sulfate having an alkyl group containing 10 to 18 carbon atoms, in particular, with sodium lauryl sulfate.
Drugs covered by this patent
- Lytgobi (futibatinib) · Taiho Oncology
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.